Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. (Q40572262)
Jump to navigation
Jump to search
scientific article published on 17 August 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. |
scientific article published on 17 August 2016 |
Statements
1 reference
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. (English)
1 reference
Patrick Marcellin
Maria Buti
Danni Colledge
Gillian Rosenberg
Darren Wong
Kathleen Jackson
Anuj Gaggar
Kathryn M Kitrinos
G Mani Subramanian
Harry L A Janssen
Ed Gane
Vitina Sozzi
Rachel Hammond
Rosalind Edwards
Alexander Thompson
17 August 2016
1 reference